Thymoquinone Loaded Solid Lipid Nanoparticles Demonstrated Antidepressant-Like Activity in Rats via Indoleamine 2, 3- Dioxygenase Pathway

Abstract

The World Health Organization (WHO) has ranked depression the 4^th leading cause of disability worldwide. Thymoquinone (TQ), is an active constituent of Nigella sativa having various medicinal properties but has poor solubility and bioavailability. This problem was overcome by developing nanoformulation of TQ. Previously TQ reported good antioxidant and anti-inflammatory effects. Recently TQ’s anti-depressant effect was demonstrated. However, the mechanisms underlying the antidepressant effect of TQ still needs evaluation. Activation of Indoleamine-2,3-dioxygenase (IDO), (an enzyme that participates in the tryptophan metabolism), leads to a decrease of serotonin (5-HT) levels. The expression of this enzyme is associated with immune system activation, which has been proposed as a common mechanism that links depression. The present study was performed in stressed animals where hippocampal levels of pro-inflammatory cytokines (IL-6 and TNF α levels), brain derived neurotropic factor (BDNF) and hippocampal kynurenine (KYN), tryptophan (TRP) and serotonin (5-HT) levels were estimated. Treatment with TQ solid lipid nanoparticles (TQSLN 20 mg/kg p.o) and TQ suspension (20 mg/kg p.o) demonstrated antidepressant-like activity in chronic forced-swim stress model. Further, it reduced the elevated hippocampal IL-6 & TNFα and reversed the increased activity of IDO as measured by ratio of hippocampal KYN/TRP and 5HT/TRP in stressed rats. The results of the present study confirm anti-inflammatory and neuroprotective effects of TQ which may be associated with 5-HT pathway. Thus, the present study offers a newer approach to reduce symptoms of depression using TQSLN. Our results are preliminary, further research is needed for more conclusive view.

Key words

Depression - Thymoquinone (TQ) - Thymoquinone solid lipid nanoparticles (TQSLN) - Forced swimming induced stress - Pro-inflammatory cytokines - BDNF

• References

• 1 World Health Organization, Depression. Fact sheet update. Retrieved from http://www.who.int/en/news-room/fact-sheets/detail/depression 2018
• 2 Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. The Lancet 1997; 349: 1498-1504
• 3 Tang M, Lei J, Sun X. et al. Stress-induced anhedonia correlates with lower hippocampal serotonin transporter protein expression. brain research 2013; 1513: 127-134
• 4 Schwarcz R, Bruno JP, Muchowski PJ. et al. Kynurenines in the mammalian brain: when physiology meets pathology. Nature Reviews Neuroscience 2012; 13: 465
• 5 O’connor JC, Lawson MA, Andre C. et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2, 3-dioxygenase activation in mice. Molecular psychiatry 2009; 14: 511
• 6 Kim H, Chen L, Lim G. et al. Brain indoleamine 2, 3-dioxygenase contributes to the comorbidity of pain and depression. The Journal of Clinical Investigation 2012; 122: 8
• 7 Sublette ME, Postolache TT. Neuroinflammation and depression: the role of indoleamine 2, 3-dioxygenase (IDO) as a molecular pathway. Psychosomatic medicine 2012; 74: 668-672
• 8 Myint AM. Kynurenines: from the perspective of major psychiatric disorders. The FEBS journal 2012; 279: 1375-1385
• 9 Ragheb A, Attia A, Eldin WS. et al. The protective effect of thymoquinone, an anti-oxidant and anti-inflammatory agent, against renal injury: a review. Saudi Journal of Kidney Diseases and Transplantation 2009; 20: 741
• 10 Badary OA, Taha RA, Gamal El-Din AM. et al. Thymoquinone is a potent superoxide anion scavenger. Drug and Chemical Toxicology 2003; 26: 87-98
• 11 Keyhanmanesh R, Boskabady MH, Eslamizadeh MJ. et al. The effect of thymoquinone, the main constituent of Nigella sativa on tracheal responsiveness and white blood cell count in lung lavage of sensitized guinea pigs. Planta medica 2010; 76: 218-222
• 12 Boudiaf K, Hurtado-Nedelec M, Belambri SA. et al. Thymoquinone strongly inhibits fMLF-induced neutrophil functions and exhibits anti-inflammatory properties in vivo. Biochemical pharmacology 2016; 104: 62-73
• 13 Bamosa AO, Kaatabi H, Lebdaa FM. et al. Effect of Nigella sativa seeds on the glycemic control of patients with type 2 diabetes mellitus. Indian J Physiol Pharmacol 2010; 54: 344-354
• 14 Yildiz F, Coban S, Terzi A. et al. Nigella sativa relieves the deleterious effects of ischemia reperfusion injury on liver. World journal of gastroenterology: WJG 2008; 14: 5204
• 15 Jaarin K, Foong WD, Yeoh MH. et al. Mechanisms of the antihypertensive effects of Nigella sativa oil in L-NAME-induced hypertensive rats. Clinics 2015; 70: 751-757
• 16 Kundu J, Chun KS, Aruoma OI. et al. Mechanistic perspectives on cancer chemoprevention/chemotherapeutic effects of thymoquinone. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2014; 768: 22-34
• 17 Cascella M, Palma G, Barbieri A. et al. Role of Nigella sativa and its constituent thymoquinone on chemotherapy-induced nephrotoxicity: evidences from experimental animal studies. Nutrients 2017; 9: 625
• 18 Tran TH, Nguyen AN, Kim JO. et al. Enhancing activity of artesunate against breast cancer cells via induced-apoptosis pathway by loading into lipid carriers. Artificial Cells, Nanomedicine, and Biotechnology 2016; 44: 1979-1987
• 19 Jafari-Aghdam N, Adibkia K, Payab S. et al. Methylprednisolone acetate–Eudragit® RS100 electrospuns: Preparation and physicochemical characterization. Artificial Cells, Nanomedicine, and Biotechnology 2016; 44: 497-503
• 20 Akhter MH, Rizwanullah M, Ahmad J. et al. Nanocarriers in advanced drug targeting: setting novel paradigm in cancer therapeutics. Artificial Cells, Nanomedicine, and Biotechnology 2018; 46: 873-884
• 21 Li H, Zhao X, Ma Y. et al. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. Journal of Controlled Release 2009; 133: 238-244
• 22 Alam M, Najmi AK, Ahmad I. et al. Formulation and evaluation of nano lipid formulation containing CNS acting drug: molecular docking, in-vitro assessment and bioactivity detail in rats. Artificial cells, nanomedicine, and biotechnology 2018; 1-2
• 23 Cryan JF, Page ME, Lucki I. Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. European journal of pharmacology 2002; 436: 197-205
• 24 Husain I, Akhtar M, Abdin MZ. et al. Rosuvastatin ameliorates cognitive impairment in rats fed with high-salt and cholesterol diet via inhibiting acetylcholinesterase activity and amyloid beta peptide aggregation. Human & Experimental Toxicology 2018; 37: 399-411
• 25 Ripoll N, David DJ, Dailly E. et al. Antidepressant-like effects in various mice strains in the tail suspension test. Behavioural Brain Research 2003; 143: 193-200
• 26 Lesniak WG, Jyoti A, Mishra MK. et al. Concurrent quantification of tryptophan and its major metabolites. Analytical biochemistry 2013; 443: 222-231
• 27 Hughes MM, Carballedo A, McLoughlin DM. et al. Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain, behavior, and immunity 2012; 26: 979-987
• 28 Ferrari AJ, Charlson FJ, Norman RE. et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS medicine 2013; 10: e1001547
• 29 Réus GZ, Jansen K, Titus S. et al. Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies. Journal of Psychiatric Research 2015; 68: 316-328
• 30 Myint AM, Schwarz MJ, Müller N. The role of the kynurenine metabolism in major depression. Journal of Neural Transmission 2012; 119: 245-251
• 31 Raison CL, Dantzer R, Kelley KW. et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-α: relationship to CNS immune responses and depression. Molecular psychiatry 2010; 15: 393
• 32 Kohsaka A, Laposky AD, Ramsey KM. et al. High-fat diet disrupts behavioral and molecular circadian rhythms in mice. Cell metabolism 2007; 6: 414-421
• 33 Cabib S, Puglisi-Allegra S. Stress, depression and the mesolimbic dopamine system. Psychopharmacology 1996; 128: 331-342
• 34 Haj-Mirzaian A, Kordjazy N, Ostadhadi S. et al. Fluoxetine reverses the behavioral despair induced by neurogenic stress in mice: role of N-methyl-d-aspartate and opioid receptors. Canadian journal of physiology and pharmacology 2016; 94: 599-612
• 35 Christmas DM, Potokar JP, Davies SJ. A biological pathway linking inflammation and depression: activation of indoleamine 2, 3-dioxygenase. Neuropsychiatric disease and treatment 2011; 7: 431
• 36 Réus GZ, Jansen K, Titus S. et al. Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies. Journal of Psychiatric Research 2015; 68: 316-328
• 37 Young JJ, Bruno D, Pomara N. A review of the relationship between proinflammatory cytokines and major depressive disorder. Journal of Affective Disorders 2014; 169: 15-20
• 38 Kubera M, Obuchowicz E, Goehler L. et al. In animal models, psychosocial stress-induced (neuro) inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011; 35: 744-759
• 39 Rizzo SS, Neal SJ, Hughes ZA. et al. Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Translational psychiatry 2012; 2: e199
• 40 Kim H, Chen L, Lim G. et al. Brain indoleamine 2, 3-dioxygenase contributes to the comorbidity of pain and depression. J Clin Invest. 2012 122. 2940-2954
• 41 Hwu P, Du MX, Lapointe R. et al. Indoleamine 2, 3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. The Journal of Immunology 2000; 164: 3596-3599
• 42 Zhao J, Gao P, Zhu D. Optimization of Zn2+-containing mobile phase for simultaneous determination of kynurenine, kynurenic acid and tryptophan in human plasma by high performance liquid chromatography. Journal of Chromatography B 2010; 878: 603-608
• 43 Baran H, Jellinger K, Deecke L. Kynurenine metabolism in Alzheimer’s disease. Journal of Neural Transmission 1999; 106: 165-181
• 44 Christmas DM, Potokar JP, Davies SJ. A biological pathway linking inflammation and depression: activation of indoleamine 2, 3-dioxygenase. Neuropsychiatric Disease and Treatment 2011; 7: 431
• 45 Dantzer R, O’Connor JC, Lawson MA. et al. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011; 36: 426-436
• 46 Laugeray A, Launay JM, Callebert J. et al. Peripheral and cerebral metabolic abnormalities of the tryptophan–kynurenine pathway in a murine model of major depression. Behavioural Brain Research 2010; 210: 84-91
• 47 Maes M, Verkerk R, Bonaccorso S. et al. Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sciences 2002; 71: 1837-1848